FDA
-
-
-
-
-
-
-
Zealand Pharma (ZEAL) Receives FDA CRL for the glepaglutide New Drug Application
-
-
-
-
-
-
-
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
-
-
-
-
-
-
-
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibro
-
-
-
-
-
-
-
Zealand Pharma Announces Financial Results for the First Half of 2023
-
-
-
-
-
-
-
Correction: Zealand Pharma Announces Full Year Results for 2022
-
-
-
-
-
-
-
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
-
-
-
-
-
-
-
"We Think There is a Good Chance of Broad-label Approval" - Needham & Company Bullish on Zealand Pharma (ZEAL) Following Phase 3 Data
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

